Article
Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent.
Gynecologic oncology - 1 Sept 2005
Barnes Mack N, Chhieng David F, Dreher Mackenzie, Jones Jennifer L, Grizzle William E, Jones Laura, Talley Lynya, Partridge Edward E
Abstract excerpt
BACKGROUND: A pilot study was undertaken to determine the feasibility of examining a COX-2 inhibitor (Celecoxib) as a chemopreventive agent in women at increased risk of ovarian cancer undergoing risk reducing salpingoophorectomy. METHODS: Women at elevated inherited risk of ovarian carcinoma pursuing risk reducing salpingoophorectomy were eligible for this trial. Ten patients were assigned to a control group...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
